Zobrazeno 1 - 10
of 845
pro vyhledávání: '"Mark A, Socinski"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Lee X. Li, Mark A. Socinski, Ganessan Kichenadasse, Christos S. Karapetis, Adel Shahnam, Ross A. McKinnon, Andrew Rowland, Ashley M. Hopkins, Michael J. Sorich
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Background Multiple studies have indicated that patients with high body mass index (BMI) may have favourable survival outcomes following treatment with an immune checkpoint inhibitor (ICI). However, this evidence is limited by several factor
Externí odkaz:
https://doaj.org/article/3c107a499ab540bd87f7273a410748e3
Autor:
Aditi Qamra, Hartmut Koeppen, Fabrice Barlesi, Federico Cappuzzo, Martin Reck, Mark A Socinski, Marcus Ballinger, Robert M Jotte, Barzin Nabet, Minu K Srivastava, Soren Muller, Tianshi Lu, Howard West, Habib Hamidi, Assaf Amitai, David S Shames
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/a3510600342247d7b4bbe2442738c4b7
Autor:
Misako Nagasaka, Danielle Brazel, Yasmine Baca, Joanne Xiu, Mohammed Najeeb Al-Hallak, Chul Kim, Jorge Nieva, Jeffrey J. Swensen, David Spetzler, Wolfgang Michael Korn, Mark A. Socinski, Luis E. Raez, Balazs Halmos, Sai-Hong Ignatius Ou
Publikováno v:
Translational Oncology, Vol 36, Iss , Pp 101744- (2023)
Background: RET fusions are driver alterations in cancer and are most commonly found in non-small cell lung cancer and well-differentiated thyroid cancer. However, RET fusion have been reported in other solid tumors. Material and methods: A retrospec
Externí odkaz:
https://doaj.org/article/be4f08bbbeef4d4185ba93c951961543
Autor:
Robert Hsu, Denaly Chen, Bing Xia, Rebecca Feldman, Wendy Cozen, Luis E. Raez, Hossein Borghaei, Chul Kim, Misako Nagasaka, Hirva Mamdani, Ari M. Vanderwalde, Gilberto Lopes, Mark A. Socinski, Antoinette J. Wozniak, Alexander I. Spira, Stephen V. Liu, Jorge J. Nieva
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundThe incidence of lung cancer in the US has been decreasing but a bigger decline has been observed in men despite similar declines in tobacco use between men and women. Multiple theories have been proposed, including exposure to exogenous es
Externí odkaz:
https://doaj.org/article/7acf7bf812854a01ad8168ea2aac8e7a
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Major advances in the diagnosis and treatment of non-small cell lung cancer (NSCLC) have resulted in a sharp decline in associated mortality rates, thereby propelling NSCLC to the forefront of precision medicine. Current guidelines recommend upfront
Externí odkaz:
https://doaj.org/article/19e5db9909304e20b06b352aad7c3c17
Autor:
Stephen V. Liu, Misako Nagasaka, Victoria Stefaniak, Kristi Gruver, Yong Lin, David Ferry, Mark A. Socinski, Li Zhang
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Sintilimab combined with pemetrexed and platinum met the primary endpoint of improving progression-free survival (PFS) as a first-line therapy for nonsquamous non-small cell lung cancer (NSCLC) in the phase 3 trial ORIENT-11 (NCT03607539). As seen in
Externí odkaz:
https://doaj.org/article/ba011ef8f8d944208052b2c5a41e42ae
Autor:
Eugene Kim, Federico Cappuzzo, Martin Reck, Wei Zou, Mark A Socinski, Mark McCleland, Makoto Nishio, Stefanie Morris, David Shames, Meghna Das Thakur, Tony SK Mok, Howard Jack West, Robert M Jotte, Geetha Shankar
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 2 (2022)
Externí odkaz:
https://doaj.org/article/9361ce1aa5b1491d8d0d29d0d749e10c
Autor:
Mark A. Socinski, Cornelius F. Waller, Tazeen Idris, Igor Bondarenko, Alexander Luft, Katrin Beckmann, Ashwini Vishweswaramurthy, Subramanian Loganathan, Charles Donnelly, Matthew A. Hummel, Roxann Shapiro, Melody Woods, Anita Rao, Vivek G Nayak, Gopinath Ranganna, Abhijit Barve
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Purpose: This phase III study compared the efficacy and safety of proposed biosimilar MYL-1402O with reference bevacizumab (BEV), as first-line treatment for patients with stage IV non-squamous non-small-cell lung cancer. Patients and methods: Patien
Externí odkaz:
https://doaj.org/article/c16131d828264fbc8bb2cf1ee253522f
Autor:
Zoe June F. Assaf, Wei Zou, Alexander D. Fine, Mark A. Socinski, Amanda Young, Doron Lipson, Jonathan F. Freidin, Mark Kennedy, Eliana Polisecki, Makoto Nishio, David Fabrizio, Geoffrey R. Oxnard, Craig Cummings, Anja Rode, Martin Reck, Namrata S. Patil, Mark Lee, David S. Shames, Katja Schulze
Publikováno v:
Nature Medicine. 29:859-868
One of the great challenges in therapeutic oncology is determining who might achieve survival benefits from a particular therapy. Studies on longitudinal circulating tumor DNA (ctDNA) dynamics for the prediction of survival have generally been small